Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2022 Mar 11;10(3):e002029corr1. doi: 10.1136/jitc-2020-002029corr1

Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy

PMCID: PMC8919435  PMID: 35277463

Wang J, Shang Z, Wang J, et al. MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. J Immunother Cancer 2021;9:e002029. doi:10.1136/jitc-2020-002029

In the original published article, the funding statement was incomplete. The “(No. 8170211 to MX)” lost a number.

The correct funding statement is: This work was supported by the National Natural Science Foundation of China (No. 81 770 211 to MX) and the National Natural Science Foundation of China (No.81830008 to JZ).


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES